EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck
Shots:
- The P-III JAVELIN Head and Neck 100 study involve assessing of Bavencio (avelumab) + CRT followed by avelumab maintenance vs CRT alone in 697 patients with previously untreated LA SCCHN
- The companies have accepted DMC’s recommendation to terminate the P-III JAVELIN Head and Neck 100 study as it did not meet its 1EPs i.e. improvement in PFS. A detailed analysis of the Phase III JAVELIN Head and Neck 100 study is being conducted and results will be shared with the scientific community
- Bavencio is a PD-L1 antibody- acts by blocking the interaction of PD-L1 with PD-1 receptors. In Nov’2014- Merck KGaA and Pfizer signed an agreement to co-develop and co-commercialize Bavencio
Click here to read full press release/ article | Ref: EMD Sereno | Image: Blau Journal
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com